30 Stocks Top Picks (NOV 16-22)

Opinion about HBC-T: Nicknames it Hit By A Car like its chart. HBC is all about its real estate holdings; that's the reason you own this. Doesn't know if the current rally signals a buy. Can't predict this chart. Even consider selling it.

Opinion about MHK-N: They had a great quarter, but so did Whirlpool and the market didn't pay attention. He prefers Whirlpool.

Opinion about DOL-T: (A Top Pick Sep 24/24, Up 42%) Traffic and basket sizes remain robust, as sticky inflation over the years has caused consumers to trade down. Bit of softness in Canadian economy for Q2 and Q3. Paying a premium at over 40x forward, but decent 15% growth rate. In Canada, very little competition.…

Opinion about BRB-T: (A Top Pick Jun 18/18, Up 1%) Still likes it. It's well-run. They're growing their brands and they have a big opportunity to get into cannabis beverages which will be legal in Canada in October 2019. BRB is well-positioned for this and this market could be very large.

Opinion about GC-T: Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Takeover offer. Pandemic hit hard. Solid assets, but re-opening slowed. Healthy balance sheet.

Browse a daily summary of experts opinions on stocks and stock investment information.

Opinion about FANG-Q: FANG vs. VLO This is the one Jim Cramer's always recommending. This one will be volatile. The one to pick if you want to have fun and make (or lose) a lot.VLO is more refineries and such. Probably looking at a nicer dividend, but slower growth. This is the one for you…

Opinion about PE-N: (A Top Pick Sep 01/20, Up 56.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PE has resulted in the company being acquired by Pioneer Natural Resources. We are considering the position now closed at the last market closing price of $16.93. Combined with the previous recommendation to cover 50%, the…

Opinion about BTE-T: (A Top Pick May 23/24, Down 48%) It's down because of the fall in oil prices, pure and simple. He sold this around $4. The stock will excel if oil returns to $70+, but not at $60. He will revisit this at better oil prices later.

Opinion about VET-T: Canadian gas is where it's at. Interesting angle with this name is that they have gas in Europe -- Ireland, Germany -- and the market's not fully reflecting these assets in the price. Well managed, good tradition of being shareholder friendly via dividends, buybacks, and managing debt well. Underappreciated. In this market, he…

Opinion about SGY-T: Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research SGY is quite small at $510M, but the stock is very cheap. With a 10% dividend, a buyer (or privatization) could eliminate the dividend and use internal cash flow to pay for the whole company in about three years. But, that doesn't…

Opinion about CPG-T: Great company. Looking at the chart, big wall of resistance it just couldn't get through. Then it broke out. If you own it, hold. If it pulls back to the neckline, he'd be all over it.

Opinion about TRP-T: He owned it for a while. Had a big run-up last year but thinks it is pretty much done now with a lot of insider selling. Tends to have big swings.

Opinion about ENB-T: The kind of stock everyone can own. Dollar-cost average in, and hold long term. Consistent, reliable, pseudo-utility though it falls under energy. Not high growth or a high ROC, as it's very capital intensive. Dividend chart and payout ratio look fantastic.

Opinion about ISC-T: (A Top Pick Feb 19/25, Up 20%) (Note the short timeframe.)  Steady business. Lots of FCF, nice dividend. Good run, but still cheap.

Opinion about CME-Q: CME Group is committed to delivering new ways to manage risk and improve efficiency. Whether that means developing product solutions to empower trading strategies, expanding access to unique data insights, seamlessly connecting siloed liquidity pools, or introducing more ways to optimize the time and capital required for world-class risk management, new opportunities…

Opinion about BAM.A-T: You could buy this but it would be better to buy the parent company, Brookfield Corporation (BN) instead, for a long term hold and outlook. BN owns 75% of BAM and has a better valuation. It has had a 15% compounded return over 10 years and expects 17% in compounded earnings. Insiders…

Opinion about WIR.UN-T: (A Top Pick Jan 12/21, Up 48%) Great-managed REIT. Taken out.

Opinion about V-N: Global leader, few competitors. Stock's come down to 200-day MA, which is always a good time to dip back in (and he did). He's held this name since 2016, adding when down and trimming when frothy. Revenue for 2026 expected to exceed $44B. Really consistent, very steady growth. Around 13-15% compounded earnings…

Opinion about AAPL-Q: Concerns about AI strategy. AI is an important piece, but not the only one for a company like this. Terrific cashflow, cash reserves. Strength in the balance sheet speaks for itself. Some of the results this week are conducive to higher returns going forward and, in turn, a higher stock price. Making…

Opinion about MSFT-Q: Stockchase Research Editor: Michael O'Reilly One has to look past its high valuation as it trades at 38x earnings and 11x book, but with a ROE of 33% it demonstrates its dominance in the space.  Recently reported earnings beat analysts estimates for revenues (by 4%) and EPS (by 9%).  Cash reserves are…

Opinion about ECL-N: Good time to buy. 

Opinion about NTR-T: World's largest crop nutrient business. Upstream production vertically integrated with downstream stores (in US, Canada, and some in South America). Commodity prices for the 3 fertilizer ingredients has bottomed, supported by steadily improving prices for major cash crops (corn, wheat, soybeans). Trades roughly at long-term average multiple. Earnings on cusp of a turning…

Opinion about SYK-N: He hasn't seen valuations like this since 2020 briefly and 1993. Their big growth driver is orthopedics with robot-assisted surgeries, with growth expected to double over 5 years; robots account for roughly 45% of their orthopedics business. (Analysts’ price target is $429.76)

Opinion about BMY-N: Has never been this cheap. Has high hopes for their new central nervous system drug; it if doesn't work, he will sell BMY.

Opinion about BIP-N: Not really affected by tariffs. In the private equity area. Probably the fastest-growing part of the business. Will continue to be quite a hot area. He prefers BN.

Opinion about SPGI-N: (A Top Pick Jun 13/24, Up 20%) All its businesses are very profitable, with operating margins in 50% range. Recurring revenue stream from subscriptions. Great businesses, very scalable. 

Opinion about H-T: (A Top Pick Jul 12/24, Up 25%) Same as Metro a year ago, when it was poised to break out, and he wanted exposure to defensives and dividends. Price momentum was improving a year ago. A long-term hold. Is down 10% this year as portfolio manager sell defence to buy offence. This…

Opinion about T-T: Mixed view. Cashflow has ticked up a bit. Pretty confident that dividend is safe. Doesn't love the valuation or the growth profile. Supposed to be low growth, but it's really low at about 2% (wants to see it go back to 5%). Yield is 7.2%, payout ratio of 43%.Hold, don't buy more;…

Opinion about BCE-T: Reported today. The plan is OK. Lots of moving parts. The turnaround from overpaying the dividend is there. Looking forward, dividend's probably safe; can probably start growing it again 3-4 years from now when the fibre play starts to pay off. Fibre is a big move to the future; if it works,…